Right Treatment, Right Patient, Right Time
Through our research into the tumor microenvironment, we are learning more about how a patient’s dynamic tumor biology can be used as a guide for treatment decisions throughout his or her cancer journey. We continue to investigate the role of?PD-L1?,?tumor mutational burden?, and gene signatures of inflammation, and other potentially predictive biomarkers – both tumor and peripheral biomarkers – to better inform and predict the benefit of current and future approaches. Additionally, our teams continue to evaluate potential diagnostic tools to help identify those biomarkers in patients leveraging less-invasive methods such as liquid biopsy.
To learn more about how Bristol-Myers Squibb is exploring the research behind why some people respond to immunotherapy and others do not,?click here.?